Xavier Pivot

Xavier Pivot

UNVERIFIED PROFILE

Are you Xavier Pivot?   Register this Author

Register author
Xavier Pivot

Xavier Pivot

Publications by authors named "Xavier Pivot"

Are you Xavier Pivot?   Register this Author

100Publications

4488Reads

48Profile Views

Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.

Breast Cancer Res Treat 2019 Oct 14. Epub 2019 Oct 14.

Department of Medical Oncology, Centre Paul Strauss, 3, rue de la Porte de l'Hôpital, BP 30042, 67065, Strasbourg, Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05439-xDOI Listing
October 2019

A new agent in the family of antibody-drug conjugates.

Lancet Oncol 2019 Aug 27;20(8):1043-1044. Epub 2019 Jun 27.

Centre Paul Strauss, Porte de l'Hopital Strasbourg, Strasbourg 67065, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30402-4DOI Listing
August 2019

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nature 2019 02;566(7742):E1

Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41586-019-0883-2
Publisher Site
http://dx.doi.org/10.1038/s41586-019-0883-2DOI Listing
February 2019

Milestones over the development of SB3, a trastuzumab biosimilar.

Future Oncol 2018 Nov 21;14(27):2795-2803. Epub 2018 Jun 21.

Department of Medical Oncology, University Hospital Of Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0270DOI Listing
November 2018

Transmission of breast cancer polygenic risk based on single nucleotide polymorphisms.

Breast 2018 Oct 14;41:14-18. Epub 2018 Jun 14.

Centre Paul Strauss, Porte de l'Hopital Strasbourg, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2018.06.006DOI Listing
October 2018

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

J Clin Oncol 2018 08 3;36(24):2465-2472. Epub 2018 Jun 3.

Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9909
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9909DOI Listing
August 2018

Can we establish a hierarchy among trastuzumab biosimilar candidates?

Br J Cancer 2018 08 13;119(3):263-265. Epub 2018 Jul 13.

Porte de l'Hopital Strasbourg, Centre Paul Strauss, Strasbourg, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0171-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068097PMC
August 2018

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey.

Prev Med Rep 2018 Jun 18;10:332-336. Epub 2018 Apr 18.

Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Department of Multidisciplinary Oncology and Therapeutic Innovations, Chemin des Bourrely, 13915 Marseille Cedex 20, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pmedr.2018.04.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984220PMC
June 2018

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.

Breast Cancer 2018 May 4;25(3):370-374. Epub 2018 Jan 4.

National Centre for Tumour Diseases, Heidelberg and Department of Gynecologic Oncology, University Hospital, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-017-0826-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906517PMC
May 2018

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

J Clin Oncol 2018 04 26;36(10):968-974. Epub 2018 Jan 26.

Xavier Pivot, University Hospital Jean Minjoz, Institut National de la Santé et de la Recherche Médicale 1098, Besançon, France; Igor Bondarenko, State Institution Dnipropetrovsk Medical, Academy of the Ministry of Health of Ukraine, Communal Institution Dnipropetrovsk City Multifield Clinical Hospital No. 4 of Dnipropetrovsk Regional Council, Dnipropetrovsk; Yuriy Vinnyk, Communal Healthcare Institution Kharkiv, Regional Clinical Oncological Center, Kharkiv; Yaroslav Shparyk, Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine; Zbigniew Nowecki, Centrum Onkologii-Instytutim. M. Sklodowskiej Curie; Tomasz Sarosiek, Magodent, Warsaw; Marek Z. Wojtukiewicz, Comprehensive Cancer Center, Medical University, Bialystok, Poland; Mikhail Dvorkin, BHI of Omsk Region, Clinical Oncology Dispensary, Omsk; Ekaterina Trishkina, SBHI Leningrad Regional Oncology Dispensary; Vladimir Moiseyenko, SBHI Saint Petersburg Scientific and Practical Center of Specialized Methods of Medical Help; Vladimir Semiglazov, FSI Scientific and Research Institution of Oncology n.a. N.N. Petrov of Ministry of Healthcare and SD of RF, St Petersburg, Russia; Jin-Hee Ahn, Asan Medical Center; Seock-Ah Im, Seoul National University Hospital, Seoul; Sujeong Song and Jaeyun Lim, Samsung Bioepis, Incheon, Republic of Korea; Sanjoy Chatterjee, Tata Medical Centre, Kolkata, India; and Maximino Bello III, St Luke's Medical Center, Quezon City, Philippines.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.0126DOI Listing
April 2018

Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey.

Curr Oncol Rep 2018 03 5;20(Suppl 1):14. Epub 2018 Mar 5.

INSERM, IRD, SESSTIM, Aix Marseille University, 23 rue Stanislas Torrents, 13006, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-017-0646-xDOI Listing
March 2018

Awareness and Misconceptions of Breast Cancer Risk Factors Among Laypersons and Physicians.

Curr Oncol Rep 2018 03 5;20(Suppl 1):15. Epub 2018 Mar 5.

INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Aix Marseille University, 23 rue Stanislas-Torrents, 13006, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-017-0647-9DOI Listing
March 2018

Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?

Chin Clin Oncol 2018 02 9;7(1). Epub 2017 Nov 9.

Breast Cancer Expert Center, APHP Tenon, IUC-UPMC Sorbonne University, Paris, France; INSERM U938, CdR St Antoine, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2017.10.07DOI Listing
February 2018

Emilia: use cunning to survive cancer.

Chin Clin Oncol 2018 02 3;7(1). Epub 2018 Jan 3.

University Hospital Jean Minjoz, INSERM 1098, Besancon, France; INSERM U1052, Centre Léon Bérard, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2017.11.04DOI Listing
February 2018

A new era for treatment development in HER2-positive breast cancer.

Lancet Oncol 2018 02 8;19(2):160-162. Epub 2018 Jan 8.

INSERM U1052, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30002-0DOI Listing
February 2018

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

J Clin Oncol 2017 Sep 3;35(25):2875-2884. Epub 2017 Jun 3.

George W. Sledge Jr., Stanford University, Stanford; Han Koh, Kaiser Permanente Medical Group, Bellflower, CA; Masakazu Toi, Kyoto University; Kenichi Inoue, Saitama Cancer Center, Saitama; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Patrick Neven, Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium; Joohyuk Sohn, Yonsei Cancer Center, Seoul, Korea; Xavier Pivot, CHU de Besancon Hopital Jean Minjoz, Besancon Cedex; Nawel Bourayou, Eli Lilly, Paris, France; Olga Burdaeva, Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Meena Okera, Adelaide Cancer Centre, Adelaide, Australia; Peter A. Kaufman, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Eva-Maria Grischke, Universitätsklinikum Tübingen Frauenklinik, Tübingen, Germany; Martin Frenzel, Yong Lin, and Ian C. Smith, Eli Lilly, Indianapolis, IN; Susana Barriga, Eli Lilly, Madrid; and Antonio Llombart-Cussac, Hospital Arnau Vilanova, Valencia, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.7585
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.7585DOI Listing
September 2017

Critical appraisal of health-state utility values used in breast cancer-related cost-utility analyses.

Breast Cancer Res Treat 2017 Aug 11;164(3):527-536. Epub 2017 May 11.

Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4283-8DOI Listing
August 2017

Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.

Breast 2017 Aug 12;34:53-57. Epub 2017 May 12.

University Hospital of Besançon, Department of Medical Oncology, France; University Hospital of Besançon, Methodology and Quality of Life in Oncology Unit, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.05.005DOI Listing
August 2017

[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys].

Bull Cancer 2017 Mar 18;104(3):258-266. Epub 2017 Jan 18.

CHRU de Tours, centre de coordination des dépistages des cancers, 37044 Tours cedex 9, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.12.002DOI Listing
March 2017

Classic cytotoxic drugs: a narrow path for regulatory approval.

Authors:
Xavier Pivot

Lancet Oncol 2017 03 11;18(3):279-281. Epub 2017 Feb 11.

University Hospital J Minjoz, 25030 Besançon Cedex 03, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045173008
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(17)30089-XDOI Listing
March 2017

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

J Clin Oncol 2017 Jan 7;35(2):141-148. Epub 2016 Nov 7.

Edith A. Perez, Mayo Clinic, Jacksonville, FL; Howard Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Jennifer A. Petersen, Genentech, South San Francisco, CA; Carlos Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre, Brazil; Wolfgang Eiermann, Interdisciplinary Oncology Center, Munich, Germany; Masakazu Toi, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Young-Hyuck Im, Samsung Medical Centre, Seoul, Korea; Pierfranco Conte, University of Padova and Istituto Oncologico Veneto, Padova, Italy; Miguel Martin, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Tadeusz Pienkowski, Postgraduate Medical Education Center, Warsaw, Poland; Xavier Pivot, University Hospital Jean Minjoz, Besançon, France; Sven Stanzel, Alexander Strasak, Monika Patre, F. Hoffmann-La Roche, Basel, Switzerland; and Paul Ellis, Guys Hospital and Sarah Cannon Research Institute, London, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.4887
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.4887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677PMC
January 2017

Cost-utility analyses of drug therapies in breast cancer: a systematic review.

Breast Cancer Res Treat 2016 Oct 30;159(3):407-24. Epub 2016 Aug 30.

Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3924-7DOI Listing
October 2016

[Prevalence and management of pain in patients with metastatic cancer in Franche-Comté].

Bull Cancer 2016 Oct 29;103(10):849-860. Epub 2016 Sep 29.

CHRU de Besançon, pôle pharmacie, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France; Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, interactions hôte-greffon-tumeur - ingénierie cellulaire et génique, Besançon, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551163022
Publisher Site
http://dx.doi.org/10.1016/j.bulcan.2016.08.007DOI Listing
October 2016

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers.

Mol Cell Oncol 2016 12;3(6):e1232186. Epub 2016 Sep 12.

Synergie Lyon Cancer, Plateforme de Bioinformatique 'Gilles Thomas' Centre Léon Bérard, Lyon, France; INRIA Grenoble-Rhône-Alpes, Montbonnot-Saint Martin, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2016.1232186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5160388PMC
September 2016

Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.

Clin Med Insights Oncol 2016 17;10:77-82. Epub 2016 Aug 17.

Department of Medical Oncology, University Hospital Jean Minjoz, Besançon cedex, France.; University of Franche-Comté, UMR1098, SFR IBCT, Besançon, France.; INSERM UMR1098, Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CMO.S38474DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990148PMC
August 2016

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.

Cancer Res 2016 07 17;76(14):4100-12. Epub 2016 May 17.

INSERM UMR1098, TIMC LabEx LipSTIC, Besançon, France. University of Bourgogne Franche-Comté, UMR1098, Besançon, France. Department of Medical Oncology, University Hospital of Besançon, Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2452DOI Listing
July 2016

A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.

Clin Ther 2016 Jul 29;38(7):1665-1673.e3. Epub 2016 Jun 29.

PAREXEL International Early Phase Clinical Unit, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2016.06.002DOI Listing
July 2016

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nature 2016 06 2;534(7605):47-54. Epub 2016 May 2.

Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature17676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910866PMC
June 2016

Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer.

Int J Gynecol Cancer 2016 Feb;26(2):261-7

*EA4267-UFR-33, School of Medecine and Pharmacy; †Medical Oncology Unit, J. Minjoz University Teaching Hospital; ‡INSERM U 645, EA-2284 IFR-133; and §Department of Surgery and ∥Pharmacy Department, J. Minjoz University Hospital, Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000592DOI Listing
February 2016

Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.

Anticancer Drugs 2015 Nov;26(10):1009-16

aDepartment of Medical Oncology, University Hospital Jean Minjoz, Besançon bFaculty of Pharmacy of Lyon cLéon Bérard Cancer Center, Lyon dGeorge François Leclerc Cancer Center, Dijon eDeparment of Radiotherapy, University Hospital Tenon, Paris fFSNB Health & Care, Paris gDepartment of Pharmacy, University Hospital Jean Minjoz, Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000287DOI Listing
November 2015

[Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].

Bull Cancer 2015 Sep 26;102(9):737-48. Epub 2015 May 26.

CHU de Besançon, hôpital Jean-Minjoz, pôle cancérologie-oncologie médicale, boulevard Fleming, 25000 Besançon cedex, France; Inserm U1098, 25000 Besançon, France; Université de Franche-Comté, SFR SMP, 25000 Besançon, France; EFS Bourgogne Franche-Comté, UMR1098, 25000 Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2015.03.021DOI Listing
September 2015

Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.

Oncologist 2015 Aug 25;20(8):873-9. Epub 2015 Jun 25.

APHP Tenon, IUC-UPMC, Sorbonne Université, Alliance Pour la Recherche en Cancérologie, Paris, France; University Hospital Jean Minjoz, UMR1098, SFR IBCT, Besançon, France; Institut du Cancer Montpellier, Université Montpellier 1, Montpellier, France; Centre Azuréen de Cancérologie, Mougins, France; Centre d'Oncologie de Gentilly, Nancy, France; APHP-St. Louis, Université Paris Diderot, Paris, France; Centre Jean-Perrin, Université d'Auvergne, Clermont-Ferrand, France; Research Unit EA 7285, University of Versailles St-Quentin, Montigny-le-Bretonneux, France; Department of Surgery, Institut Curie, Saint-Cloud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524752PMC
August 2015

Cancer screening in France: third edition of the EDIFICE survey.

Eur J Cancer Prev 2015 Jun;24 Suppl:S68-72

aCoordination Center for Cancer Screening, Bretonneau University Hospital, Tours bDepartment of Oncology and Hematology, Paul-Brousse University Hospital, Inserm U1004, Villejuif cKantar Health, Montrouge dPorte de Saint-Cloud Clinic, Boulogne-Billancourt eRoche, Boulogne-Billancourt fLéon Bérard Cancer Centre, Lyon gDepartment of Medical Oncology, Jean Minjoz University Hospital, Besançon hCancer Control Department, Paoli-Calmettes Institute iAix Marseille University, UMR_S912, IRD jINSERM, UMR912 (SESSTIM), Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CEJ.0000000000000146DOI Listing
June 2015

Breast cancer screening controversy: too much or not enough?

Eur J Cancer Prev 2015 Jun;24 Suppl:S73-6

aDepartment of Medical Oncology, Jean Minjoz University Hospital, Inserm U645, Besançon bCoordination Center for Cancer Screening, Bretonneau University Hospital, Tours cKantar Health, Montrouge dDepartment of Oncology and Hematology, Paul-Brousse University Hospital, Inserm U1004, Villejuif eLéon Bérard Cancer Centre, Lyon fPorte de Saint-Cloud Clinic, Boulogne-Billancourt gRoche, Boulogne-Billancourt hCancer Control Department, Paoli-Calmettes Institute iAix Marseille University, UMR_S912, IRD jINSERM, UMR912 (SESSTIM), Marseille, France.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/eurjcancerprev/2015/07001/Breas
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CEJ.0000000000000145DOI Listing
June 2015

Social stratification, risk factor prevalence and cancer screening attendance.

Eur J Cancer Prev 2015 Jun;24 Suppl:S77-81

aCancer Control Department, Paoli-Calmettes Institute bAix Marseille University, UMR_S912, IRD cINSERM, UMR912 (SESSTIM), Marseille dCoordination Center for Cancer Screening, Bretonneau University Hospital, Tours eKantar Health, Montrouge fPorte de Saint-Cloud Clinic, Boulogne-Billancourt gRoche, Boulogne-Billancourt hDepartment of Medical Oncology, Jean Minjoz University Hospital, Inserm U645, Besançon iLéon Bérard Cancer Centre, Lyon jDepartment of Oncology and Hematology, Paul-Brousse University Hospital, Inserm U1004, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CEJ.0000000000000144DOI Listing
June 2015

Lung cancer risks, beliefs and healthcare access among the underprivileged.

Eur J Cancer Prev 2015 Jun;24 Suppl:S82-6

aDepartment of Oncology and Hematology, Paul-Brousse University Hospital, Inserm U1004, Villejuif bCoordination Center for Cancer Screening, Bretonneau 2 University Hospital, Tours cKantar Health, Montrouge dDepartment of Medical Oncology, Jean Minjoz University Hospital, Inserm U645, Besançon eLéon Bérard Cancer Centre, Lyon fPorte de Saint-Cloud Clinic, Boulogne-Billancourt gRoche, Boulogne Billancourt hDepartment of Cancer Control, Paoli-Calmettes Institute iAix Marseille University, UMR_S912, IRD jINSERM, UMR912 (SESSTIM), Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CEJ.0000000000000143DOI Listing
June 2015

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

J Clin Oncol 2015 May 20;33(14):1564-73. Epub 2015 Jan 20.

Xavier Pivot, Centre Hospitalier Universitaire, Hôpital Jean Minjoz, Besançon, France; Alexey Manikhas, St Petersburg City Oncology Dispensary; Vladimir Semiglazov, Petrov Research Institute of Oncology, St Petersburg, Russian Federation; Bogdan Żurawski, Franciszek Lukaszczyk Oncology Center, Bydgoszcz; Ewa Chmielowska, Centrum Onkologii im. Prof Franciszka Lukaszczyka Oddzial Kliniczny Onkologii, Bydgoszcz, and Uniwersytet Mikolaja Kopernika Torun, Torun; Boguslawa Karaszewska, Przychodnia Lekarska KOMED, ul Wojska Polskiego 6, Konin, Poland; Rozenn Allerton, The Royal Wolverhampton Hospitals National Health Service Trust, Wolverhampton; Stephen Chan, Nottingham University Hospital, Nottingham; Roma Parikh and Fareha Nagi, GlaxoSmithKline, Uxbridge, United Kingdom; Alessandra Fabi, "Regina Elena" National Cancer Institute, Rome; Paolo Bidoli, Azienda Ospedaliera San Gerardo di Monza U.O. Oncologia Medica, Monza, Lombardia; Stefania Gori, Azienda Ospedaliera di Perugia, Ospedale S. Maria della Misericordia, Struttura Complessa di Oncologia Medica, Perugia, Umbria, and Azienda Ospedaliera Sacro Cuore-Don Calabria-Negrar, Negrar, Verona, Italy; Eva Ciruelos, Hospital Universitario 12 de Octubre, Madrid, Spain; Magdolna Dank, SE Radiológiai és Onkoterápiás Klinika; Lajos Hornyak, Veszprém Megyei Csolnoky Ferenc Kórház, Onkológiai Osztály, Budapest, Hungary; Sara Margolin, Karolinska University Hospital, Stockholm, Sweden; Arnd Nusch, Gem Praxis Drs Nusch, Kalhori und Langer, Friedrichstr, Velbert, Germany; and Michelle DeSilvio, Sergio Santillana, and Ramona F. Swaby, GlaxoSmithKline, Collegeville, PA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/14/1564.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.1794
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.1794DOI Listing
May 2015

In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?

Oncologist 2015 Apr 20;20(4):344-50. Epub 2015 Mar 20.

Departments of Medical Oncology, Gynecology, Pathology, and Statistics, University Hospital Jean Minjoz, Besançon, France; University of Franche-Comté, UMR1098, SFR IBCT, Besançon, France; INSERM, UMR1098, Besançon, France; EFS Bourgogne Franche-Comté, UMR1098, Besançon, France; Genomic Health, Inc., Redwood City, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391758PMC
April 2015

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.

Cancer Med 2014 Dec 11;3(6):1502-11. Epub 2014 Aug 11.

Department of Medical Oncology, University Hospital of Besançon, Besançon, France; Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298376PMC
December 2014

First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.

J Oncol Pharm Pract 2014 Oct 24;20(5):362-8. Epub 2013 Oct 24.

Department of Pharmacy, University Teaching Hospital of Besançon, France INSERM U645 EA-2284 IFR-133, University of Franche-Comté, Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155213508440DOI Listing
October 2014

[Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].

Bull Cancer 2014 Jul-Aug;101(7-8):681-9

Inserm U645 EA-2284 IFR-133, Université de Franche-Comté, 25000 Besançon, France, CHU de Besançon, Oncologie médicale, Hôpital Jean Minjoz, boulevard Fleming 25030 Besançon cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2014.1923DOI Listing
September 2014

Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions.

Breast 2014 Apr 22;23(2):165-9. Epub 2013 Dec 22.

Department of Medical Oncology, Besançon University Hospital, Besançon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.12.003DOI Listing
April 2014

Arthralgia and aromatase inhibitors.

Joint Bone Spine 2014 Mar 13;81(2):187-8. Epub 2013 Aug 13.

Department of Oncology, CHRU, University Teaching Hospital, and University of Franche-Comté, Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2013.06.011DOI Listing
March 2014

Adjuvant chemotherapy for local relapse breast cancer.

Authors:
Xavier Pivot

Lancet Oncol 2014 Feb 16;15(2):125-6. Epub 2014 Jan 16.

Jean-Minjoz University Hospital, Centre Hospitalier Universitaire de Besançon, 25030 Besançon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70610-7DOI Listing
February 2014

Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.

J Immunother 2014 Jan;37(1):51-4

*Oncologie, Besançon Cedex §CIC-BT506, CHRU †INSERM, UMR1098 ‡UMR1098, Université de Franche-Comté ∥EFS Bourgogne Franche-Comté ¶Laboratoire de Pharmacologie Clinique et Toxicologie, Besançon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000006DOI Listing
January 2014

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

Breast 2013 Oct 17;22(5):650-6. Epub 2013 Aug 17.

Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.07.037DOI Listing
October 2013

Specific anticancer treatments in the last 3 months of life: a French experience.

Support Care Cancer 2013 Feb 27;21(2):405-12. Epub 2012 Jun 27.

Medical Oncology Unit, CHU of Tours, Bretonneau Hospital, 2 Boulevard Tonnellé, 37000, Tours, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-012-1529-1DOI Listing
February 2013

First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.

Anticancer Res 2012 Aug;32(8):3547-52

Department of Pharmacy, University Hospital, 3 Boulevard Fleming, 25030 BESANCON Cedex, France.

View Article

Download full-text PDF

Source
August 2012